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Abstract 
Drug development is expensive and prone to failure. It is potentially much 
less risky and expensive to reuse a drug developed for one condition for 
treating a second disease, than it is to develop an entirely new 
compound. Systematic approaches to this drug repositioning are needed 
to increase throughput and find candidates more reliably. Here we 
address this need with an integrated systems biology dataset, developed 
using the Ondex data integration platform, for the in silico discovery of 
new drug repositioning candidates. We demonstrate that the information 
in this dataset allows known repositioning examples to be discovered. We 
also propose a means of automating the search for new treatment 
indications of existing compounds. 
1 Introduction 
The drug development process is increasing in cost and becoming less productive. In 
order to arrest the decline in the productivity curve, pharmaceutical companies, 
biotechnology companies and even academic researchers are turning to systems 
biology approaches to discover new uses for existing pharmacotherapies, and in 
some cases, reviving abandoned ones [1]. Here, we describe the use of the Ondex 
data integration platform for this purpose.  
1.1 Drug Repositioning 
There is recognition in the pharmaceutical industry that the current paradigm of 
research and development needs to change. Drugs based on novel chemistry still 
take 10-15 years to reach the market, and development costs are usually between 
$500 million and $2 billion [2][3].  Most novel drug candidates fail in or before the 
clinic, and the costs of these failures must be borne for the companies concerned by 
those drug candidates that do reach the market. These costs make it difficult even for 
large pharmaceutical companies to bring truly new drugs to market, and are 
completely prohibitive for publicly-funded researchers.  An alternative means of 
discovering new treatments is to find new uses for existing drugs or for drug 
candidates for which there is substantial safety data.  This repositioning approach 
bypasses the need for many of the pre-approval tests required of completely new 
therapeutic compounds, since the agent has already been documented as safe for its 
original purpose [4].   
There are a number of examples where a new use for a drug has been discovered 
by a chance observation. New uses have been discovered for drugs from the 
observation of interesting side-effects during clinical trials, or by drug administration 
for one condition having unintended effects on a second. Sildenafil is probably the 
best-known example of the former; this drug was developed by Pfizer as a treatment 
for pulmonary arterial hypertension; during clinical trials, the serendipitous discovery 
was made that the drug was a potential treatment of erectile dysfunction in men. The 
direction of research was changed and sildenafil was renamed “Viagra” [5]. 
In order that a systematic approach may be taken to repositioning, a methodology 
that is less dependent on chance observation is required for the identification of 
compounds for alternative use.  For instance, duloxetine (Cymbalta) was originally 
developed as an anti-depressant, and was postulated to be a more effective 
alternative to selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine 
(Prozac). However, a secondary indication, as a treatment for stress urinary 
incontinence was found by examining its mode of action [6].   
However, performing such an analysis on a drug-by-drug basis is impractical, time 
consuming and inappropriate for systematic screens. Systems biology provides a 
complementary method to manual reductionist approaches, by taking an integrated 
view of cellular and molecular processes. Combining data integration technology with 
systems approaches facilitates the analysis of an entire knowledgebase at once, 
and is therefore more likely to identify promising leads. 
1.2 The Ondex data integration and visualisation platform 
Biological data exhibit a wide variety of technical, syntactic and semantic 
heterogeneity. To use these data in a common analysis regime, the differences 
between them need to be tackled, giving them a common semantics. Different data 
integration platforms tackle this complicated problem in a variety of ways. BioMart 
[7], for instance, relies on transforming disparate database schema into a unified 
Mart format, which can then be accessed through a standard query interface. On the 
other hand, systems such as the Distributed Annotation System (DAS) take a 
federated approach to data integration; leaving data on multiple, distributed servers 
and drawing it together on a client application to provide an integrated view [8]. 
Ondex is a data integration platform for Systems Biology [9], which addresses the 
problem of data integration by representing many types of data as a network of 
interconnected nodes.  By allowing the nodes (or concepts) and edges (or relations) 
of the graph to be annotated with semantically rich metadata, multiple sources of 
information can be brought together meaningfully in the same graph. So, each 
concept has a Concept Class, and each relation a Relation Type. In this way it is 
possible to encode complex biological relationships within the graph structure; for 
example, two concepts of class Protein may be joined by an interacts_with relation, 
or a Transcription Factor may be joined to a Gene by a regulates relation. The Ondex 
data structure also allows both concepts and relations to have attributes, accessions 
and names. This feature means that almost any information can be attached to the 
graph in a systematic way. The parsing mechanism also records the provenance of 
the data in the graph. Ondex data is stored in the OXL data format [10], a custom 
XML format designed for the exchange of integrated datasets, and closely coupled 
with the design of the data structure of Ondex. 
The Ondex framework therefore combines large-scale database integration with 
sequence analysis, text mining and graph-based analysis. The system is not only 
useful for integrating disparate data, but can also be used as a novel analysis 
platform.  
Using Ondex, we have built an integrated dataset of around 120,000 concepts and 
570,000 relations to visualise the links between drugs, proteins and diseases. We 
have included information from a wide variety of publicly available databases, 
allowing analysis on the basis of: drug molecule similarity; protein similarity; tissue 
specific gene expression; metabolic pathways and protein family analysis.  We 
analysed this integrated dataset to highlight known examples of repositioned drugs, 
and their connectivity across multiple data sources. We also suggest methods of 
automated analysis for discovery of new repositioning opportunities on the basis of 
indicative semantic motifs. 
2 Methods 
The general methods used are typical of any Ondex workflow.  Parsers import data 
into the OXL data format [10], using the Ondex integration backend; mappers and 
transformers are then used to join different data sets, remove unconnected nodes 
and add additional information to the network.  As a final step, the network is 
analysed for interesting examples of repositioning by manually traversing the data 
using Ondex. 
2.1 The Data Sources 
The data included in the drug repositioning dataset was limited to publicly available 
sources, to enable its wide redistribution. The databases and analysis methods used 
to generate the dataset were: DrugBank [11], UniProt [12], HPRD [13], KEGG [14], 
PFam [15], SymAtlas [16], G-Sesame [17], OpenBabel [18] and BLAST [19]. The 
cross references from UniProt are used to include accession numbers from many 
other linked datasets (e.g. OMIM, ENSEMBL, GO, PRINTS and more).  
 
2.2 The Integration Workflow 
Figure 1 summarises the Ondex workflow used to produce the dataset for this study. 
For the following Concepts and Relations are italicised.  
Considering first the Concepts: 
- From DrugBank, we take Compounds (called “Drugs” in DrugBank) and 
Targets 
- From UniProt, we take Proteins 
- From SymAtlas, we take Affymetrix Probes and their associated expression 
values 
- From KEGG, we take Pathways and other associated information.  
Next, the Relations: 
- Targets and Proteins are linked by UniProt accession mapping 
- From HPRD, we take interactions between Proteins 
- Affymetrix Probes are linked to Proteins using UniProt accession mapping 
- From PFAM, we take family relations between Proteins 
Finally, relationships that are annotated with a numerical value: 
- G-Sesame semantic similarity scores were added to Protein interactions 
- Sequence similarity scores were added between Proteins, using BLAST 
- Structural similarity scores were added between Compounds, using 
OpenBabel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Ondex data integration workflow used to generate the data for this 
study.  Heterogeneous data sources are parsed into Ondex OXL format, and 
mappers & transformers applied to create new relations between them. 
HPRD protein-protein interaction relations were scored using G-Sesame, a semantic 
similarity measure for the Gene Ontology [17].  Partners of a protein interaction were 
assessed based on the semantic distance of their Cell Compartment GO terms 
(parsed from HPRD), proteins with a low score are likely to be in different parts of the 
cell, and therefore unlikely to be able to physically interact in vivo.  
BLAST mapping was used to draw similarity relations between Proteins in the 
dataset (using an e-value cutoff of 0.0001), and OpenBabel was used to run 2D-
Tanimoto over the compounds in DrugBank and draw similarity relations between 
them (using a similarity cutoff of 0.85 [20]). 
2.3 The Metagraph 
The Ondex metagraph shows the connections between the ConceptClasses and 
RelationTypes in the main network. Figure 2 shows a subset of the metagraph for the 
repositioning dataset. It provides an overview of the overall structure of the data. A 
total of 29 RelationTypes and 15 ConceptClasses are present in the complete 
dataset.  
 
Figure 2 – A subset of the metagraph of the Ondex drug repositioning dataset. 
Some ConceptClasses and RelationTypes have been removed for clarity. 
Drugs taken from DrugBank are actually of ConceptClass Compound but are 
called Drug here to avoid confusion with Compound concepts taken from 
KEGG.  
2.4 Data availability 
The data presented and analysed in this study are available in the supplementary 
materials.  All of the code used to generate the graph can be found in the Ondex 
Subversion repository, which is freely available from http://www.ondex.org/. 
2.5 Exploring and filtering the data 
Ondex provides a visualisation platform, which enables browsing of graphs loaded 
from data in OXL format. This platform features many filters, annotators and layout 
algorithms for finding information efficiently in a large integrated dataset. We can 
examine the interactions of any drug in detail. A filter reduces the network to just that 
drug and its immediate neighbourhood. This small network can be expanded to 
include relations of interest using further neighbourhood filters (e.g. by examining the 
neighbours of proteins that the drug binds to). Concepts and Relations can be 
coloured based on data they are annotated with (such as BLAST e-value, or 
Tanimoto coefficient). 
3 Results & Discussion 
3.1 Chlorpromazine 
The motivation for building this Ondex dataset for drug and protein interaction data is 
to find examples of molecules that might have a therapeutic purpose additional to 
those already known.  The first stage of this process is to look for examples of drugs 
that already have a known additional use to see if both indications can be found in 
the data. We consider, here, the example of chlorpromazine (Thorazine). The 
discovery of this drug resulted from a search for new and more effective 
antihistamines in the 1930s and 40s. It was one of a series of compounds shown, as 
well as being antihistaminic, to have greater sedative and anti-emetic effects than 
previous drugs. On the basis of these effects, the original proposed use of 
chlorpromazine was as a post-surgical therapy [21].  However, treatment with 
chlorpromazine goes beyond simple sedation; patients also demonstrate 
improvements in emotional behaviour.  It was this observed activity that led to it 
being trialled as an anti-psychotic. Chlorpromazine was eventually approved, and is 
used, for both purposes [22].  
Chlorpromazine, in the Ondex drug repositioning network (DrugBank accession 
number DB00477), has seven immediate neighbours (Figure 3A). Three of these 
neighbours are targets – D(2) Dopamine Receptor, 5-hydroxytryptamine 2A Receptor 
and Serum Albumin – and four are similar drugs – trimeprazine, promazine, 
prochlorprezine and perphenazine.  Expanding the network to include the first 
neighbours of the targets of chlorpromazine, results in a graph with two clusters. 
Chlorpromazine, being the central node, connects to both clusters (Figure 3C).  Two 
of the targets of chlorpromazine– D(2) Dopamine Receptor and 5-hydroxytryptamine 
2A receptor – are present in the largest cluster, while the other – Serum Albumin – 
forms the hub of the second cluster.  Binding to serum albumin is common amongst 
cationic drugs such as chlorpromazine and serves to reduce bioavailability. This 
binding is probably responsible for some side-effects, but is not clinically relevant 
[23].  The larger cluster contains the two targets mentioned above, several related 
proteins (other similar receptors) and a large number of other drugs, many of which 
bind both targets, and most of which are also anti-psychotics (e.g. clozapine, 
haloperidol and loxapine).  Also included in these drugs are three of the four 
compounds that are structurally similar to chlorpromazine (promazine, 
prochlorprezine and perphenazine).    It is known that the interaction of 
chlorpromazine with the D(2) dopamine receptor is central to its anti-psychotic 
activity [24].  The interaction of chlorpromazine with the 5-hydroxytryptamine 2A 
receptor has anti-aggressive and anti-depressive effects, and also attenuates the 
extra-pyramidal side-effects that are common, and undesirable, with anti-psychotic 
drugs [25]. 
These two clusters of drug-target interactions involve all of the first neighbours of 
chlorpromazine apart from one: trimeprazine (DrugBank accession DB01246).  
Unlike the other three drugs similar to chlorpromazine, this drug does not seem to 
bind the same receptors; it therefore seems unlikely to have the same function. To 
examine the function of trimeprazine, a network of its first neighbours was drawn 
(Figure 3B).  Trimeprazine has just one recognised target in DrugBank, the histamine 
H1 receptor.  Drugs binding to this receptor generally have a vasodilatory and 
antiemetic effect (trimeprazine is primarily used as a travel sickness treatment), as 
well as an antihistaminic effect. 
This similarity between chlorpromazine and trimeprazine, a known antagonist of the 
histamine H1 receptor, might suggest a molecular mechanism for the anti-emetic 
mode of action of chlorpromazine.  The similarity of the two drugs suggests that they 
both bind the receptor with similar effects.  This interaction is not detailed directly in 
DrugBank because it is a fully curated database [26], and contains only interactions 
reported in the primary literature. 
3.2 Other repositioning examples 
Other known examples of drugs that have been repositioned can be identified in the 
Ondex network. The original use of Celecoxib was as a treatment for arthritis, but 
more recently it has been shown to also be effective against colo-rectal cancer [4].  
Celecoxib (DrugBank accession DB00482) binds two targets, COX2 and 3-
phosphoinositide-dependent protein kinase 1. The binding with COX2 explains the 
drug’s original use, as a treatment for arthritis. 
In the Ondex network, 3-phosphoinositide-dependent protein kinase 1 (encoded by 
PDPK1) is shown by the information parsed from KEGG to be involved in a number 
of cancers. PDKP1 is also shown to possess sequence similarity with AKT1. KEGG 
information in the network indicates that AKT1 is involved specifically in colorectal 
cancer, which helps to explain the role of celecoxib in treating this disease. 
Mifepristone (DrugBank accession DB00834) found its first use as an abortifacient, a 
function which is explained by its binding to the progesterone receptor. The second 
use of the drug, as a treatment for psychotic major depression, is also directly 
explained by binding, of mifepristone to the glucocorticoid receptor [27]. 
Figure 3 – Chlorpromazine is circled in red in all panels. A – First neighbours 
of chlorpromazine in the Ondex graph. B – First neighbours of trimeprazine 
and its protein target, histamine H1 receptor. C – First neighbours of 
chlorpromazine and the protein targets to which it binds. D(2) Dopamine 
receptor (group 1), 5-hydroxytryptamine 2A receptor (group 2) and Serum 
Albumin (group 3). The red arrow indicates trimeprazine, which is not involved 
in the same groups of interactions as the other neighbours of chlorpromazine. 
Ondex colour scheme – drugs are represented by green stars, targets are pink 
circles and proteins are red circles. 
3.3 Semantic Motifs 
Browsing the large Ondex network for known examples of repositioning is a simple 
matter. It demonstrates that the information is of real utility in highlighting potential 
new purposes for drugs.  It is not, however, a viable approach for analysing the 
whole graph for possible new drugs and targets of interest.  For such a search, 
methods are needed to uncover regions of interest in the graph.  To this end, we 
propose one method to exploit the semantically rich information of the Ondex graph 
model to extract semantic motifs: subgraphs, or motifs, that match a particular 
metadata, or semantic, structure. 
Chlorpromazine is structurally similar to trimeprazine; trimeprazine binds to a target 
(Histamine H1 Receptor); however, chlorpromazine itself is not known to interact with 
the H1 receptor (Figure 4A). We can represent this set of relationships as: 
drug (1) – similar to – drug (2) – binds to – target 
This is an abstract semantic motif; the syntax shows Concept (x) – Relation – 
Concept (y) [...] where x and y indicate different members of the same ConceptClass. 
This semantic motif may indicate that our knowledge of an interaction of drug (1) with 
target is missing. More complex semantic motifs are possible, as shown in figure 4C. 
For example: 
drug – binds to – target – is a – protein (1) – involved in – disease (1) – 
similar to – protein (2) – involved in – disease (2) 
The motif above suggests that the drug with a therapeutic impact on disease (1) may 
have an impact on disease (2). In both of these cases, the semantic motif identifies 
areas that may merit further investigation.  
 
 
Figure 4 – Semantic motifs of possible interest in the context of the Ondex 
drug repositioning network. A – An instance of the abstract motif shown in B, 
that is found in the Ondex subnetwork that explains the repositioning of 
Chlorpromazine (discussed in section 3.1). B – An abstract representation of 
the semantic motif, of which A is the archetype. C – An abstract semantic 
motif that implicates a drug as having an impact on a disease(2), due to the 
similarity between two proteins involved in separate disease processes. 
It is possible to apply these semantic motifs within Ondex, since they exploit the 
semantic richness of the Concepts and Relations, following particular paths through 
the network based on the Concept Classes and Relation Types of the entities 
encountered.  Other graph-based analysis systems lack the detailed metadata that is 
required for such an analysis. Cytoscape is a popular network browsing and analysis 
tool that facilitates the annotation of nodes and edges. However, these terms are not 
required to be drawn from a controlled vocabulary and the facilities to relate terms 
with an ontology are not part of the core functionality [28]. Tools such as Medusa [29] 
and BioLayout Express [30] lack the ability to handle graphs of the scale of the one 
reported here. Further software such as Osprey [31] and ProViz [32] do not have the 
rich Ondex Application Programming Interface (API) that allows custom graph 
algorithms to be implemented. 
3.4 Limitations of this approach 
The approval and administration of drugs is an evidence-based practice. Evidence is 
required that the drug in question is more effective than a referent, such as a placebo 
or existing drug, at treating the condition concerned, and does not have dangerous 
side effects.  An understanding of the molecular action of a drug is not required for 
approval.  Consequently, there is a great deal of missing information about the 
molecular targets of many drugs and the involvement of specific proteins in particular 
diseases.  These gaps in the knowledgebase mean many potential repositioning 
opportunities will be missed, as the data that are required to identify them in this way 
do not exist. 
There is a possibility that in leveraging data such as that found in the Ondex network, 
information that is known is simply being recapitulated in a new form. Particularly 
when searching for examples of drugs that are known to have been repurposed. 
However, the chlorpromazine example shows that even when information is held to 
be true, it is not necessarily represented within the databases being integrated. 
Therefore it is possible to derive new knowledge from the network analysis for even 
well-studied examples. 
Searching for semantic motifs will return many hits.  For example, the simple motif 
abstraction in Figure 4B has 26,693 instances in the repositioning graph. It is likely 
that a large proportion of these results will not be true repositioning possibilities, and 
will not turn out to be useful.  This problem may be ameliorated somewhat by the 
implementation of a robust scoring function for semantic motifs.  There are a number 
of measures in the dataset that could assist in the construction of such an algorithm, 
such as the Tanimoto coefficient, BLAST e-values, G-Sesame scores for protein-
protein interactions, and tissue-specific expression values.  By prioritising the 
consideration of high scoring motifs, and those drugs that appear in a number of 
different motifs, it is possible that many true positives could be prioritised. 
4 Conclusions 
Ondex is a data integration platform for systems biology. Critically, the datasets that 
it generates employ metadata that represents more of the semantic richness of the 
biological knowledge. In this paper, we have investigated drug repositioning using a 
custom-built dataset. We have shown that this integrated dataset can uncover 
knowledge suitable for discovery of additional therapeutic uses for drugs. We 
suggest a mechanism, semantic motifs, which can exploit both the dataset and its 
semantic richness.  
Ideally, a systems biology model would have complete knowledge of the biological 
system, however, the normal practice of biology and drug discovery means that this 
is always lacking. An integrated dataset may provide us with some of the information 
we need for these models; here we have also suggested that they can be used to 
highlight gaps in existing knowledge by searching for semantic motifs. 
In conclusion, we have shown that adding additional semantics into an integrative 
bioinformatics approach using Ondex can support repositioning and drug discovery, 
and could provide a rich underpinning for future systems biology. 
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